Summary of Krystal Biotech FY Conference Call Company Overview - **Company**: Krystal Biotech (NasdaqGS:KRYS) - **Key Product**: VYJUVEK, a treatment for patients with moderate to mild wounds Core Industry Insights - **Sales Force Expansion**: The expansion of the U.S. sales force has significantly improved reimbursement approvals, with over 660 approvals reported, growing at approximately 45+ per quarter [2][15] - **Label Update Impact**: The recent label update allowing for at-home self-dosing is expected to be a medium to long-term growth driver, enhancing patient compliance and demand [2][4][6] - **Growth Dynamics for 2026**: - **Rest of World (ROW) Sales**: Expected to be a major growth driver, particularly in Germany, Italy, France, and Japan, where patient compliance is high [12][24] - **U.S. Market**: Growth will also depend on the start-stop regimen dynamics, as many patients have been on the drug for three years and are mostly healed [14][20] Key Financial Metrics - **Reimbursement Approvals**: Currently at 660, with a goal of reaching 720 in the near future [15] - **Sales Growth**: ROW sales are anticipated to surpass U.S. sales due to a larger identified patient population in Europe and Japan [24] Pipeline Developments - **Ocular Program**: - Increased dosing frequency for KB803 in ocular DEB and KB801 in NK to accommodate at-home self-dosing, with pivotal trials needing re-enrollment [28][30] - Emphasis on patient safety and compliance in home settings, leading to a design change in dosing regimens [52][56] - **CF Program**: - Ongoing positive discussions with the FDA regarding molecular correction data, with expectations for updates on the CORAL-3 design [236][240] - Collaboration with CFF and TDN Foundation has been fruitful, with excitement around the data generated [238][244] Regulatory and Market Considerations - **Pricing Negotiations**: Ongoing discussions in Germany, France, the UK, and Spain, with expectations for pricing clarity in Q3 for Germany and next year for France [24][25] - **Market Entry Strategy**: The decision to self-launch in key markets was based on unmet medical needs and regulatory hurdles [22] Additional Insights - **Patient Compliance**: The ability for patients to self-administer VYJUVEK is expected to improve compliance, especially for older patients who may be reluctant to wait for nurse visits [6][20] - **Operational Challenges**: The transition from clinical to home settings presents challenges in ensuring proper administration and compliance, which the company is addressing through increased dosing frequency [162][193] Conclusion Krystal Biotech is positioned for growth in 2026, driven by strategic sales force expansion, favorable label updates, and a robust pipeline. The company is actively addressing regulatory challenges and focusing on patient compliance to enhance market penetration and sales performance.

Core Insights - Krystal Biotech (KRYS) reported Q4 2025 earnings per share (EPS) of $1.70, exceeding the Zacks Consensus Estimate of $1.62, and up from $1.52 in the same quarter last year [1][7] - Revenues for the quarter were $107.1 million, a 17.5% increase year over year, but fell short of the Zacks Consensus Estimate of $109 million, with all revenues coming from Vyjuvek sales [1][6] - The FDA approved Vyjuvek, the first revocable gene therapy, for treating dystrophic epidermolysis bullosa (DEB) in patients aged six months and older, and for at-home administration [2] Financial Performance - For Q4 2025, product revenues from Vyjuvek were $107.1 million, up from $91.1 million in the previous year, driven by strong patient uptake, with a gross margin of 94% [6][7] - For the full year 2025, total product revenues reached $389.1 million, a 34% increase year over year, with net earnings of $6.84 per share compared to $3.00 in 2024 [10] Market Access and Demand - The company secured over 660 reimbursement approvals for Vyjuvek in the U.S., facilitating nationwide access, while international demand remains strong with over 90 patients prescribed the therapy in Germany, France, and Japan [3][7] Research and Development - R&D expenses for Q4 were approximately $14.8 million, a 9.36% increase year over year, while SG&A expenses totaled about $41.4 million, up 32.5% due to increased headcount and marketing costs [8] - Krystal Biotech is advancing multiple candidates, including KB407 and KB707, with several data readouts and studies planned for 2026 [7][12] Pipeline Updates - KB407 is being evaluated for cystic fibrosis, with successful data from a multicenter study announced in January, and a registrational study planned for 2026 [13][14] - KB707 is in development for solid lung tumors, with the FDA granting RMAT designation for advanced non-small cell lung cancer [18] - The company is also developing KB304 for aesthetic applications, with a mid-stage study expected to start in 2027 [19]

Core Insights - Krystal Biotech reported strong revenue growth for Q4 2025 and full-year 2025, with net revenue from VYJUVEK reaching $107.1 million in Q4 and $389.1 million for the year, representing approximately 34% year-over-year growth [3][4][6] Financial Performance - R&D expenses for Q4 2025 were $14.8 million, up from $13.5 million a year earlier, while SG&A expenses increased to $41.4 million from $31.3 million, primarily due to higher headcount and costs associated with global launches [1] - Gross margin remained strong at 94% for both the quarter and the full year, with expectations to maintain margins in the 90% to 95% range for the foreseeable future [2] Market Expansion - The company is experiencing momentum in international markets, particularly in Europe and Japan, with over 90 DEB patients prescribed VYJUVEK across these regions [13] - U.S. commercial momentum is also strong, with more than 660 reimbursement approvals and over 500 unique prescribers since launch [6][9] Pipeline Developments - Krystal is advancing multiple programs, including KB407 for cystic fibrosis, with expected registrational readouts before year-end [5][18] - Protocol changes for KB801 and KB803 aim to facilitate at-home dosing, with data expected before year-end [19][20] Cash Position - The company ended 2025 with $955.9 million in cash and investments, providing a strong financial foundation for future growth [8]

Financial Data and Key Metrics Changes - The company reported net VYJUVEK revenue of $107.1 million in Q4 2025, marking a growth of almost 10% compared to the previous quarter and approximately 18% year-over-year [26][27] - Year-to-date VYJUVEK net revenue reached $389.1 million, an increase of approximately 34% compared to full year 2024 revenue [26] - Gross margin for Q4 was 94%, down from 96% in Q3 and 95% in Q4 of 2024, attributed to increased sales outside the U.S. which carry higher costs [27] Business Line Data and Key Metrics Changes - The U.S. commercial performance showed strong momentum with over 660 reimbursement approvals since launch and over 500 unique prescribers [10] - In Europe, the launch of VYJUVEK is progressing well, with over 90 DEB patients prescribed the treatment across Germany, France, and Japan [12][16] - The company aims to expand its distributor agreements to over 40 countries in 2026, having already signed agreements covering more than 20 countries [5] Market Data and Key Metrics Changes - The company is experiencing strong demand for VYJUVEK in various markets, with significant patient adoption in Germany and Japan [12][16] - Pricing negotiations are ongoing in Germany and France, with expectations to finalize agreements in the second half of 2026 for Germany and in 2027 for France [13][16] Company Strategy and Development Direction - The company is focused on expanding global access for VYJUVEK while advancing a pipeline of genetic therapies, with plans to initiate two additional registrational programs later in the year [6][34] - The strategy includes disciplined capital allocation and a commitment to self-launching new indications if approved [8][34] - The company is also exploring stock buyback options but prioritizes investments in its pipeline and potential M&A opportunities [52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential from international markets, noting that there are more DEB patients outside the U.S. than within it [32] - The company anticipates that revenue may not track linearly with patient counts due to accruals and ongoing pricing negotiations [33] - Management highlighted the importance of registrational programs and the positive impact of recent FDA designations on development timelines [25][34] Other Important Information - The company ended the year with $955.9 million in combined cash and investments, positioning it well for future commercial launches and pipeline milestones [31] - The company received a Fast Track designation for KB111 and an RMAT designation for KB707, which can accelerate development timelines [25] Q&A Session Summary Question: Visibility into Q1 and contribution from ex-U.S. vs U.S. in 2026 - Management indicated that while ex-U.S. markets will be the predominant growth driver, U.S. demand is also accelerating, with expectations to break out revenue in Q1 [36][38] Question: Compliance rates in EU and Japan - Compliance in Europe is similar to the U.S. at launch, but Japan has a two-week prescription requirement that may affect long-term compliance [44][48] Question: Updates on pricing negotiations in Europe - Management expects to reach a pricing agreement in Germany in Q3 and anticipates that negotiations in France will extend into the first half of next year [55][56] Question: Changes in dosing regimens for ocular studies - The modified dosing regimens were designed to enhance patient compliance and convenience, with no changes to the dose volume or potency [75][76] Question: Patient distribution for VYJUVEK in Europe - Management noted that estimating patient numbers in Europe is challenging due to varying laws and logistics, but they are optimistic about the launch progress [63][64]

Financial Data and Key Metrics Changes - The company reported Q4 2025 net revenue of $107.1 million, marking a growth of almost 10% compared to the prior quarter and approximately 18% growth year-over-year [26][27] - Year-to-date net revenue for VYJUVEK reached $389.1 million, an increase of approximately 34% compared to full year 2024 revenue [26] - Gross margin for Q4 was 94%, down from 96% in Q3 and 95% in Q4 of 2024, attributed to increased sales outside the U.S. which carry higher costs [27] Business Line Data and Key Metrics Changes - VYJUVEK continues to show strong performance with total net revenue since launch exceeding $730 million [8] - The company added over 50 new prescribers in Q4 2025, reaching over 500 unique prescribers since launch in the U.S. [10] - In Europe, over 90 DEB patients have been prescribed VYJUVEK across Germany, France, and Japan, with ongoing momentum in Germany and France [12][13] Market Data and Key Metrics Changes - The company has signed distributor agreements covering more than 20 countries, aiming to expand to over 40 countries in 2026 [5] - Pricing negotiations in Germany and France are ongoing, with expectations for agreements in the second half of 2026 for Germany and 2027 for France [13][16] - The company has expanded its distributor network to include Israel, enhancing its market presence [16] Company Strategy and Development Direction - The company aims to build a durable commercial gene therapy business with disciplined capital allocation and a focus on expanding global access for VYJUVEK [7] - The strategy includes investing behind measurable execution milestones and advancing a focused pipeline, with plans to initiate two additional registrational programs later this year [6][8] - The company is committed to optimizing processes to support patients and providers, leveraging partnerships with advocacy organizations [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential from international markets, noting that there are more DEB patients outside the U.S. than within [31] - The company anticipates that revenue may not track linearly with patient counts due to accruals and ongoing pricing negotiations [32] - Management highlighted the importance of registrational programs and expressed optimism about upcoming clinical data readouts [33] Other Important Information - The company ended the year with $955.9 million in combined cash and investments, positioning it well for future commercial launches and pipeline milestones [30] - The company received Fast Track designation for KB111 and RMAT designation for KB707, which can accelerate development timelines [25] Q&A Session Summary Question: Visibility into Q1 and 2026 revenue contribution from U.S. vs. ex-U.S. - Management indicated that while ex-U.S. markets will be the predominant growth driver, demand in the U.S. is also accelerating, with expectations to break out revenue in Q1 [35][36] Question: Data supporting modified dosing regimens for ocular and NK - Management confirmed that the changes were made to enhance patient compliance and convenience, with confidence in the safety profile of the drugs [38][39] Question: Compliance rates in EU and Japan - Management noted that compliance in Europe has been similar to the U.S., but highlighted a potential burden in Japan due to the two-week prescription requirement [42][46] Question: Updates on pricing negotiations in Europe - Management expects to reach a pricing agreement in Germany in the second half of the year, while negotiations in France may extend into the first half of next year [53] Question: Impact of modified dosing regimens on study data - Management confirmed that the data generated to date will be included in the primary analysis, with no changes to the dose volume [73][75]

Financial Data and Key Metrics Changes - The company reported Q4 2025 net revenue of $107.1 million, marking a growth of almost 10% compared to the previous quarter and approximately 18% year-over-year [25][26] - Year-to-date net revenue for VYJUVEK reached $389.1 million, an increase of approximately 34% compared to full year 2024 revenue [25] - Gross margin for Q4 was 94%, down from 96% in Q3 2025 and 95% in Q4 2024, attributed to increased sales outside the U.S. which carry higher costs [26] Business Line Data and Key Metrics Changes - VYJUVEK continues to show strong performance with total net revenue since launch exceeding $730 million [6] - The company has signed distributor agreements covering more than 20 countries, aiming to expand to over 40 countries in 2026 [4] - The U.S. market saw over 660 reimbursement approvals, with more than 500 unique prescribers since launch [9] Market Data and Key Metrics Changes - In Europe, over 90 DEB patients have been prescribed VYJUVEK across Germany, France, and Japan, with sustained prescription growth in Germany [11][12] - The launch in Japan has been successful, with a unique distribution model enabling home delivery [13] - Pricing negotiations are ongoing in Germany and France, with expectations for agreements in the second half of 2026 and 2027 respectively [12][14] Company Strategy and Development Direction - The company is focused on expanding global access for VYJUVEK while advancing a disciplined pipeline of gene therapies [5] - Plans to initiate two additional registrational programs in cystic fibrosis and Hailey-Hailey disease later this year [5] - The company aims to build a durable commercial gene therapy business with strong capital allocation and operational improvements [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing demand for VYJUVEK, particularly in international markets, which are expected to drive revenue growth in 2026 [30] - The company is aware of the evolving utilization patterns among U.S. patients, shifting towards more intermittent treatment cycles [31] - Management remains optimistic about the potential of their pipeline programs, especially with recent FDA designations that could accelerate development timelines [33] Other Important Information - The company ended the year with $955.9 million in cash and investments, positioning it well for future commercial launches and pipeline milestones [29] - R&D expenses for Q4 were $14.8 million, while SG&A expenses were $41.4 million, reflecting increased headcount and marketing costs [27] Q&A Session Summary Question: Visibility into Q1 and 2026 revenue contribution from U.S. vs. ex-U.S. - Management indicated that while growth will predominantly come from ex-U.S. markets, demand in the U.S. is also accelerating, with expectations to break out revenue in Q1 [36] Question: Data supporting modified dosing regimens for ocular and NK - Management confirmed that the changes were based on patient feedback and the need for home administration, ensuring compliance and convenience [40] Question: Compliance rates in EU and Japan - Compliance in Europe has been consistent with the U.S., while Japan's two-week prescription requirement may affect long-term compliance [46] Question: Updates on pricing negotiations in Europe - Management expects to reach a pricing agreement in Germany in the second half of 2026, while negotiations in France may extend into 2027 [54] Question: Differentiating factors for dosing schedules in ocular studies - The decision for different dosing regimens was based on patient convenience and feedback, with no changes to the dose volume [70]

Fourth Quarter and Full Year 2025 Financial and Operating Results February 17, 2026 © Copyright 2026 Krystal Biotech, Inc. All rights reserved. Forward Looking Statements and Disclosures This presentation and our discussion contain forward-looking statements that involve substantial risks and uncertainties. Any statements about future expectations, plans, and prospects for Krystal Biotech, Inc. (together with its subsidiaries, the "Company"), including but not limited to, statements about our U.S., Germany, ...

Financial Performance - The company reported $107.1 million in net product revenue for the fourth quarter of 2025, an increase from $91.1 million in the same quarter of 2024, representing a growth of approximately 17.5% [6][19][36] - For the full year 2025, net product revenue totaled $389.1 million, up from $290.5 million in 2024, indicating a year-over-year increase of about 34% [19][38] - The gross margin for the fourth quarter and full year of 2025 was 94% [6] - The company ended the quarter with a strong balance sheet, holding $955.9 million in cash and investments [1][19] Product Development and Pipeline - VYJUVEK, the company's gene therapy product for dystrophic epidermolysis bullosa (DEB), has secured over 660 reimbursement approvals in the U.S. and has seen high patient demand in Germany, France, and Japan, with over 90 patients prescribed the therapy [6][22] - The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707 for advanced non-small cell lung cancer (NSCLC) and Fast Track Designation to KB111 for Hailey-Hailey disease (HHD) [1][12][13] - The company is advancing its clinical trials, including a Phase 1 study for KB407 in cystic fibrosis, which showed successful lung delivery and expression of the CFTR protein [5][14] Future Outlook - The company aims to launch multiple products and treat over 10,000 patients with rare diseases by the end of 2030, with ongoing discussions for pricing negotiations in Germany and France expected to continue into 2026 and 2027 [2][6] - The company is on track to expand its specialty distributor network to cover over 40 countries by the end of 2026 [6] - The company expects to report interim efficacy data for KB707 and plans to initiate a registrational study for KB111 in HHD in the second half of 2026 [13][14]

Core Insights - Krystal Biotech, Inc. (NASDAQ:KRYS) is recognized as one of the top 10 growth stocks on NASDAQ for the next decade, with multiple analysts raising their price targets significantly, indicating strong future potential [1][3][5] Price Target Adjustments - Goldman Sachs raised its price target from $206 to $327, suggesting a 16.7% upside from current levels [1] - Clear Street increased its price target from $288 to $338, indicating a further 20.7% upside [3] - Bank of America adjusted its price target from $288 to $318, reflecting a 13.8% upside [5] Growth Programs - The company is focusing on short-term growth through three registrational programs: KB801, KB803, and KB407, with potential product launches expected around 2028 [1] - Ophthalmic programs are viewed as de-risked and scalable, leveraging the existing Vyjuvek commercial platform [2] Market Opportunities - KB407 is seen as a promising opportunity in cystic fibrosis, with long-term potential contingent on additional FEV1 data [2] - The neurotrophic keratitis market is a significant source of investor interest, particularly driven by KB801, which contributed to the upward revision of price targets [4] Company Overview - Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on developing genetic medicines for diseases with high unmet medical needs, with products including VYJUVEK, KB105, KB104, KB407, and KB707 [6]

Core Insights - Krystal Biotech, Inc. (KRYS) anticipates preliminary unaudited net product revenues of $106-$107 million from its lead drug Vyjuvek in Q4 2025, raising the full-year 2025 revenue forecast to $388-$389 million, driven by strong uptake in the U.S. and successful launches in Europe and Japan [1][11] Financial Performance - At the end of 2025, Krystal reported approximately $955 million in cash, cash equivalents, and investments, providing substantial financial flexibility for clinical programs [2] - For 2026, the company expects combined non-GAAP R&D and SG&A expenses to be between $175-$195 million [2] Pipeline Development - Krystal is advancing several rare disease programs utilizing its redosable HSV-1 gene therapy platform, targeting high-turnover tissues such as skin, lung, and eye [3] - Key pipeline candidates include KB803 for ocular complications of DEB, KB801 for neurotrophic keratitis, KB407 for cystic fibrosis, and KB111 for Hailey-Hailey disease [3] Clinical Trials and Updates - Enrollment in the registrational KB801 study has increased to 60 patients, indicating potential for expedited development, with a detailed update expected in February 2026 [4] - Top-line data from the KB801 and KB803 registrational studies are anticipated in 2026, serving as important near-term catalysts [6] - Other targets for 2026 include initiating and completing enrollment in a registrational repeat dose study for KB407 and starting a double-blind, placebo-controlled study for KB111 [7] Vyjuvek Developments - Vyjuvek received FDA approval in May 2023 as the first revocable gene therapy for treating patients aged six months or older with dystrophic epidermolysis bullosa (DEB) [8] - In September 2025, a label update expanded the treatment-eligible population to include DEB patients from birth and allowed for greater dosing flexibility [9][12] Long-term Strategy - The company aims to have at least four marketed rare disease therapies by 2030, targeting over 10,000 patients globally while maintaining profitability [5] - Krystal continues to invest in earlier-stage programs for larger indications, including KB408 for alpha-1 antitrypsin deficiency and KB707 for non-small cell lung cancer, which could provide long-term growth potential [5] Stock Performance - Shares of KRYS increased by 5% on January 9, with a notable 73.9% rise over the past year compared to the industry growth of 19.6% [16]